Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018

  • ID: 4586012
  • Report
  • 2103 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • eFFECTOR Therapeutics Inc
  • Hybrigenics SA
  • MediGene AG
  • Pharma Mar SA
  • MORE
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights:

This latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 16, 120, 105, 7, 171, 24 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 18, 16, 1, 35 and 18 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • eFFECTOR Therapeutics Inc
  • Hybrigenics SA
  • MediGene AG
  • Pharma Mar SA
  • MORE
Introduction

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Pty Ltd, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

List of Figures

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AB Science SA
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Aeglea BioTherapeutics Inc
  • Affichem SA
  • Agios Pharmaceuticals Inc
  • Aileron Therapeutics Inc
  • AIMM Therapeutics BV
  • AlfaSigma SpA
  • Altor BioScience Corp
  • Amgen Inc
  • Amplia Therapeutics Pty Ltd
  • Angiocrine Bioscience Inc
  • Antigen Express Inc
  • Antisense Therapeutics Ltd
  • APIM Therapeutics AS
  • Aprea AB
  • Aptevo Therapeutics Inc
  • arGEN-X BV
  • Ariad Pharmaceuticals Inc
  • Arog Pharmaceuticals Inc
  • Array BioPharma Inc
  • Arrien Pharmaceuticals LLC
  • Ascentage Pharma Group Corp Ltd
  • Aslan Pharmaceuticals Pte Ltd
  • Astellas Pharma Inc
  • Asterias Biotherapeutics Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athenex Inc
  • Aurigene Discovery Technologies Ltd
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BCI Pharma SA
  • Beactica AB
  • Bellicum Pharmaceuticals Inc
  • BerGenBio ASA
  • Bio-Cancer Treatment International Ltd
  • Bio-Path Holdings Inc
  • BioLineRx Ltd
  • Bionomics Ltd
  • BioSight Ltd
  • Blueprint Medicines Corp
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • Cancer Therapeutics CRC Pty Ltd
  • Cantargia AB
  • Cantex Pharmaceuticals Inc
  • Celgene Corp
  • Cell Medica Ltd
  • CellCentric Ltd
  • Celldex Therapeutics Inc
  • Cellectis SA
  • Cellerant Therapeutics Inc
  • Cellular Biomedicine Group Inc
  • Celyad SA
  • CharlestonPharma LLC
  • ConverGene LLC
  • CrystalGenomics Inc
  • CSPC Pharmaceutical Group Limited
  • CTI BioPharma Corp
  • Cyclacel Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • DC Prime BV
  • Deciphera Pharmaceuticals LLC
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Emercell SAS
  • EntreChem SL
  • Epizyme Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Forma Therapeutics Inc
  • Formula Pharmaceuticals Inc
  • Fortress Biotech Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corporation
  • Gadeta BV
  • Gamida Cell Ltd
  • GC Pharma
  • Genentech Inc
  • Genoscience Pharma
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GlycoMimetics Inc
  • Glycostem Therapeutics BV
  • Golden Biotechnology Corp
  • GT Biopharma Inc
  • H3 Biomedicine Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hoverink Biotechnologies Inc
  • Hummingbird Bioscience Pte Ltd
  • Hutchison MediPharma Ltd
  • Hybrigenics SA
  • Igenica Biotherapeutics Inc
  • IGF Oncology LLC
  • Ignyta Inc
  • Imago BioSciences Inc
  • Immune System Key Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Innovation Pharmaceuticals Inc
  • Intellia Therapeutics Inc
  • Interprotein Corp
  • Io Therapeutics Inc
  • Iovance Biotherapeutics Inc
  • Jasco Pharmaceuticals LLC
  • Jazz Pharmaceuticals Plc
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • JW Pharmaceutical Corp
  • Kainos Medicine Inc
  • Karyopharm Therapeutics Inc
  • Kiadis Pharma NV
  • Kiromic Inc
  • Kite Pharma Inc
  • Komipharm International Co Ltd
  • Kura Oncology Inc
  • Kyowa Hakko Kirin Co Ltd
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Leukos Biotech SL
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc
  • Mateon Therapeutics Inc
  • MaxCyte Inc
  • MediGene AG
  • MedImmune LLC
  • Medivir AB
  • MEI Pharma Inc
  • Merck & Co Inc
  • Merck KGaA
  • Merus NV
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • Miragen Therapeutics Inc
  • Mirati Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • Moleculin Biotech LLC
  • MolMed SpA
  • NantKwest Inc
  • Nerviano Medical Sciences Srl
  • NewLink Genetics Corp
  • Nohla Therapeutics Inc
  • Northern Biologics Inc
  • Novartis AG
  • Omeros Corp
  • OncoImmune Inc
  • Onconova Therapeutics Inc
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Otsuka Holdings Co Ltd
  • Oxford BioTherapeutics Ltd
  • Oxstem Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Pharmedartis GmbH
  • Philogen SpA
  • Phylogica Ltd
  • Picobella LLC
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Protheragen Inc
  • PTC Therapeutics Inc
  • Rafael Pharmaceuticals Inc
  • Rich Pharmaceuticals Inc
  • Samumed LLC
  • Sanofi
  • Sapience Therapeutics Inc
  • Sareum Holdings Plc
  • Seattle Genetics Inc
  • SELLAS Life Sciences Group Inc
  • Selvita SA
  • Senhwa Biosciences Inc
  • Sensei Biotherapeutics Inc
  • Sierra Oncology Inc
  • Spectrum Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • Storm Therapeutics Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sunesis Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • SYNIMMUNE GmbH
  • Syros Pharmaceuticals Inc
  • TaiGen Biotechnology Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • Takara Bio Inc
  • Takeda Pharmaceutical Co Ltd
  • TC BioPharm Ltd
  • Teva Pharmaceutical Industries Ltd
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • Trillium Therapeutics Inc
  • Trovagene Inc
  • VasGene Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • Vichem Chemie Research Ltd
  • Viralytics Ltd
  • Vyriad Inc
  • Xencor Inc
  • Zenith Epigenetics Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll